BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33331955)

  • 1. Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug.
    Federico A; Mantovani E; Casari R; Bertoldi A; Lugoboni F; Tamburin S
    J Neural Transm (Vienna); 2021 Jul; 128(7):1109-1119. PubMed ID: 33331955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult Attention-Deficit/Hyperactivity Disorder and Quality of Life in High-Dose Benzodiazepine and Related Z-Drug Users.
    Lugoboni F; Bertoldi A; Casari R; Mantovani E; Morbioli L; Tamburin S
    Eur Addict Res; 2020; 26(4-5):274-282. PubMed ID: 32570244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients.
    Tamburin S; Federico A; Morbioli L; Faccini M; Casari R; Zamboni L; Briguglio G; Lugoboni F
    Am J Addict; 2017 Sep; 26(6):610-614. PubMed ID: 28570753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in substance use disorder patients with and without attention deficit hyperactivity disorder 12 months after treatment: a naturalistic follow-up study.
    Flores-García L; Lensing MB; Ytterstad E; Eisemann M
    Atten Defic Hyperact Disord; 2019 Sep; 11(3):299-310. PubMed ID: 30903585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of Quality of Life in High-Dose Benzodiazepine Misusers.
    Tamburin S; Federico A; Faccini M; Casari R; Morbioli L; Sartore V; Mirijello A; Addolorato G; Lugoboni F
    Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28054975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
    Lugoboni F; Zamboni L; Mantovani E; Cibin M; Tamburin S;
    Eur Addict Res; 2020; 26(4-5):263-273. PubMed ID: 31995807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everyday life consequences of substance use in adult patients with a substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD): a patient's perspective.
    Kronenberg LM; Slager-Visscher K; Goossens PJ; van den Brink W; van Achterberg T
    BMC Psychiatry; 2014 Sep; 14():264. PubMed ID: 25234344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study.
    Federico A; Tamburin S; Maier A; Faccini M; Casari R; Morbioli L; Lugoboni F
    Neurol Sci; 2017 Jan; 38(1):137-142. PubMed ID: 27730361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
    Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
    BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults.
    Young JT; Carruthers S; Kaye S; Allsop S; Gilsenan J; Degenhardt L; van de Glind G; van den Brink W; Preen D
    Drug Alcohol Rev; 2015 Nov; 34(6):683-93. PubMed ID: 25790353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
    BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Diagnosis in Patients with Substance Use Disorder and/or Attention-Deficit/Hyperactivity Disorder Using Continuous Performance Test.
    Slobodin O; Blankers M; Kapitány-Fövény M; Kaye S; Berger I; Johnson B; Demetrovics Z; van den Brink W; van de Glind G
    Eur Addict Res; 2020; 26(3):151-162. PubMed ID: 32074617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year follow-up of the effectiveness and mediators of cognitive behavioural therapy among adults with attention-deficit/hyperactivity disorder: secondary outcomes of a randomised controlled trial.
    Pan MR; Dong M; Zhang SY; Liu L; Li HM; Wang YF; Qian QJ
    BMC Psychiatry; 2024 Mar; 24(1):207. PubMed ID: 38491411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial.
    van Emmerik-van Oortmerssen K; Vedel E; Koeter MW; de Bruijn K; Dekker JJ; van den Brink W; Schoevers RA
    BMC Psychiatry; 2013 May; 13():132. PubMed ID: 23663651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial.
    van Emmerik-van Oortmerssen K; Vedel E; Kramer FJ; Blankers M; Dekker JJM; van den Brink W; Schoevers RA
    Drug Alcohol Depend; 2019 Apr; 197():28-36. PubMed ID: 30769263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturalistic exploratory study of the associations of substance use on ADHD outcomes and function.
    MacDonald B; Sadek J
    BMC Psychiatry; 2021 May; 21(1):251. PubMed ID: 33980212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and correlates of ADHD in individuals with substance use disorder in Nigeria.
    Umar MU; Salihu AS; Owolabi SD
    Atten Defic Hyperact Disord; 2017 Sep; 9(3):189-198. PubMed ID: 28097536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
    van Emmerik-van Oortmerssen K; van de Glind G; Koeter MW; Allsop S; Auriacombe M; Barta C; Bu ET; Burren Y; Carpentier PJ; Carruthers S; Casas M; Demetrovics Z; Dom G; Faraone SV; Fatseas M; Franck J; Johnson B; Kapitány-Fövény M; Kaye S; Konstenius M; Levin FR; Moggi F; Møller M; Ramos-Quiroga JA; Schillinger A; Skutle A; Verspreet S; ; van den Brink W; Schoevers RA
    Addiction; 2014 Feb; 109(2):262-72. PubMed ID: 24118292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.